Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a

Status Completed

Clinical Trial Summary

The aim of this study is to improve the diagnostic of Lewy body dementia by combining the scintigraphy (SPECT) usig a spécific transporter and magnetic resonance imaging (MRI).

Clinical Trial Description

Lewy body dementia is the second leading cause of dementia in France after degenerative Alzheimer's disease.

However its dignosis is difficult. Its comes in large part from the similarity of symptoms with another close dementia syndrome : the Alzheimer disease . Therfore, its is very important to have a mean to distinguish between the two dementias.

One highlight of the Lewy body dementia process being dopaminergic degeneration, the use of specific radioactive tracers is thought to be the way. The radiotracer that has the greatest advantage for these explorations is currently the DaTSCAN because it binds specifically on the dopamine transporter and can be used in Single photon emission computed tomography (SPECT).

The aim of this study is to improve the performance of imaging in the diagnosis of dementia by combining scintigraphy (SPECT) and magnetic resonance imaging (MRI) in the exploration of the striatal region . The development of this method applied to a population of subjects, with hallucinations and cognitive disorders, should demonstrate the value and complementarity of metabolic images (SPECT) and morphological (MRI) within the differential diagnosis of Lewy body dementia and the Alzheimer disease .

From a methodological point of view, the patient will be included in hospital and will have a clinical diagnosis defined according to the criteria of dementia NINCDS-ADRDA for the Alzheimer disease and Mc-Keith criteria for Lewy body dementia. Their MMSE will be over 18 and they have in common recurrent visual hallucinations.

After the inclusion, two steps must be distinguished, a neuropsychological evaluation stage and an scitigraphy exploration . Before the SPECT , all patients should have an MRI. ;

Study Design

Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00820937
Study type	Interventional
Source	University Hospital, Limoges
Contact
Status	Completed
Phase	N/A
Start date	March 2006
Completion date	March 2008

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05497817` - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia	N/A
Not yet recruiting	`NCT05499429` - Non-invasive Transcranial Focused Low-intensity Ultrasound Stimulation in Patients With Mild Lewy Body Dementia	N/A
Recruiting	`NCT06337578` - Advances in Telephone-based Cognitive Screening Procedures
Terminated	`NCT02871427` - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder	Phase 2
Completed	`NCT03305809` - A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Phase 2
Completed	`NCT00209456` - Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia	Phase 3
Recruiting	`NCT06263673` - Anti-Diabetic Medications to Fight PD and LBD	Phase 4
Recruiting	`NCT06389032` - PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia	N/A
Terminated	`NCT05778695` - Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones	N/A
Active, not recruiting	`NCT05524181` - Telehealth-enabled Integrated Palliative Care for People With Dementia	N/A
Completed	`NCT01339130` - Assessment of Social-emotional Functioning in Neurological Diseases	N/A
Completed	`NCT04413851` - Feasibility of Passive Data Collection in Dementia Subjects With Agitation
Recruiting	`NCT03233646` - Retinal Imaging in Neurodegenerative Disease
Completed	`NCT02860338` - COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE	N/A
Recruiting	`NCT05779839` - A Study of Caregiver Connections Via Technology in Dementia	N/A
Completed	`NCT03550131` - Innovations in Dementia Empowerment and Action	N/A
Completed	`NCT02640729` - Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia	Phase 2
Recruiting	`NCT03019757` - Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Recruiting	`NCT05826457` - North American Prodromal Synucleinopathy Consortium Stage 2
Recruiting	`NCT06005935` - Environmental and Reproductive Health Risk for Lewy Body Dementia

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI) — DatScan

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms